Surinabant

Surinabant (SR 147778) is an orally active, selective cannabinoid receptor type 1 CB1R antagonist. Surinabant is used in studies of obesity and alcoholism[1][2].

ChEBI: 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-3-pyrazolecarboxamide is a member of pyrazoles and a ring assembly.

[1] Klumpers LE, et al. Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans. Br J Clin Pharmacol. 2013 Jul;76(1):65-77. DOI:10.1111/bcp.12071
[2] Fischler PV, et al. Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review. Front Pharmacol. 2022 Oct 3;13:927703. DOI:10.3389/fphar.2022.927703